Determination of Regulatory Review Period for Purposes of Patent Extension; SPINRAZA

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for SPINRAZA, a human drug product, following the submission of patent extension applications to the US Patent and Trademark Office (USPTO). The FDA is publishing this notice as required by law.